Riccardo Sarzani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4865482/publications.pdf

Version: 2024-02-01

120 papers 4,158 citations

32 h-index 61 g-index

125 all docs

125 docs citations

125 times ranked

6359 citing authors

#	Article	IF	Citations
1	Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers. European Journal of Preventive Cardiology, 2022, 28, e10-e13.	1.8	9
2	Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. Internal and Emergency Medicine, 2022, 17, 329-338.	2.0	13
3	Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality. Mechanisms of Ageing and Development, 2022, 202, 111636.	4.6	15
4	Routine laboratory parameters, including complete blood count, predict COVID-19 in-hospital mortality in geriatric patients. Mechanisms of Ageing and Development, 2022, 204, 111674.	4.6	16
5	Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211027.	2.5	11
6	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the realâ€ife setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	6.0	21
7	Continuous spinal infusion of prilocaine in high-risk surgical patients: a reply. Minerva Anestesiologica, 2021, 87, 621-622.	1.0	O
8	The Number of Pills, Rather Than the Type of Renin–Angiotensin System Inhibitor, Predicts Ambulatory Blood Pressure Control in Essential Hypertensives on Triple Therapy: A Real-Life Cross-Sectional Study. Advances in Therapy, 2021, 38, 4013-4025.	2.9	5
9	Reply to: The role of continuous spinal anesthesia in covid-19 pandemic. Minerva Anestesiologica, 2021, 87, 1149-1150.	1.0	O
10	Prevalence and predictors of subclinical atrial fibrillation in hospitalized older adults. Aging, 2021, 13, 17024-17037.	3.1	1
11	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. Journal of Hypertension, 2021, 39, 376-380.	0.5	20
12	The Identikit of Patient at Risk for Severe COVID-19 and Death: The Dysregulation of Renin-Angiotensin System as the Common Theme. Journal of Clinical Medicine, 2021, 10, 5883.	2.4	3
13	Statin therapy is associated with better ambulatory blood pressure control: a propensity score analysis. Journal of Hypertension, 2020, 38, 546-552.	0.5	18
14	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. PLoS ONE, 2020, 15, e0237297.	2.5	51
15	Effect of sacubitril/valsartan on renal function: a systematic review and metaâ€analysis of randomized controlled trials. ESC Heart Failure, 2020, 7, 3487-3496.	3.1	44
16	Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19. Internal and Emergency Medicine, 2020, 15, 885-887.	2.0	9
17	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	2.7	330
18	Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 349-362.	2.2	34

#	Article	IF	Citations
19	Prevalence of Subclinical Carotid Atherosclerosis and Role of Cardiovascular Risk Factors in Older Adults: Atherosclerosis and Aging are Not Synonyms. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 231-238.	2.2	8
20	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L325-L336.	2.9	69
21	A 95-year-old patientÂwith unexpected coronavirus disease 2019 masked by aspiration pneumonia: a case report. Journal of Medical Case Reports, 2020, 14, 82.	0.8	3
22	Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid―diuretics that protect from target organ damage and cardiovascular events. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1622-1632.	2.6	14
23	Electronic cigarette use among Italian smokers: patterns, settings, and adverse events. Tumori, 2020, 106, 229-240.	1.1	7
24	Thoracic continuous spinal anesthesia for high-risk comorbid older patients undergoing major abdominal surgery: one-year experience of an Italian geriatric hospital. Minerva Anestesiologica, 2020, 86, 261-269.	1.0	19
25	Vascular, Metabolic and Musculoskeletal Diseases: From Experimental to Clinical Research. , 2020, , 185-201.		o
26	Covid-19 and the role of smoking: the protocol of the multicentric prospective study COSMO-IT (COvid19 and SMOking in ITaly). Acta Biomedica, 2020, 91, e2020062.	0.3	3
27	Title is missing!. , 2020, 15, e0237297.		O
28	Title is missing!. , 2020, 15, e0237297.		0
29	Title is missing!. , 2020, 15, e0237297.		0
30	Title is missing!. , 2020, 15, e0237297.		O
31	Title is missing!. , 2020, 15, e0237297.		0
32	Title is missing!., 2020, 15, e0237297.		O
33	Validation of an easy questionnaire on the assessment of salt habit: the MINISAL-SIIA Study Program. European Journal of Clinical Nutrition, 2019, 73, 793-800.	2.9	14
34	Ambulatory blood pressure and arterial stiffness webâ€based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive) Tj ETQq0 (0 0 2gBT /(Ove nh ock 10 Tf
35	Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC Pulmonary Medicine, 2019, 19, 171.	2.0	11
36	Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Internal and Emergency Medicine, 2019, 14, 1287-1297.	2.0	45

#	Article	IF	CITATIONS
37	Response to: "Oldest Old With Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Noninvasive Ventilation: 2 Planets Approaching― Journal of the American Medical Directors Association, 2019, 20, 923-924.	2.5	O
38	Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Oldest Adults: Predictors of In-Hospital Mortality and Need for Post-acute Care. Journal of the American Medical Directors Association, 2019, 20, 893-898.	2.5	24
39	Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded "Double-Trouble―Lipid Profile in Overweight/Obese. Advances in Therapy, 2019, 36, 1426-1437.	2.9	30
40	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661988812.	2.6	12
41	Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. Scientific Reports, 2019, 9, 19178.	3.3	14
42	PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides. International Journal of Molecular Sciences, 2019, 20, 245.	4.1	32
43	Prognostic role of masked and white-coat hypertension: 10-Year mortality in treated elderly hypertensives. Journal of Human Hypertension, 2019, 33, 741-747.	2.2	15
44	N-terminal pro B-Type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 629-635.	2.6	13
45	Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation. Respiration, 2018, 95, 22-29.	2.6	7
46	Reply. Journal of Hypertension, 2018, 36, 445.	0.5	0
47	Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives. Journal of the American Medical Directors Association, 2018, 19, 342-347.	2.5	19
48	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.8	48
49	Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clinic Proceedings, 2018, 93, 980-990.	3.0	10
50	Tenâ€year changes in ambulatory blood pressure: The prognostic value of ambulatory pulse pressure. Journal of Clinical Hypertension, 2018, 20, 1230-1237.	2.0	18
51	Interarm blood pressure differences predict target organ damage in type 2 diabetes. Journal of Clinical Hypertension, 2017, 19, 472-478.	2.0	16
52	Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers. Journal of Hypertension, 2017, 35, 2315-2322.	0.5	8
53	Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 115-126.	2.2	53
54	Blood Pressure and Metabolic Changes After 3-Month CPAP Therapy in a Very Elderly Obese with Severe Obstructive Sleep Apnea: A Case Report and Review of the Literature. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 341-346.	2.2	4

#	Article	IF	CITATIONS
55	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
56	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
57	Pcsk9 is expressed in human visceral adipose tissue and regulated by insulin and the lipolytic natriuretic peptide in cultured human adipocytes. Atherosclerosis, 2017, 263, e222.	0.8	1
58	Relationship between NT-proBNP levels and serum lipid profile in very elderly hospitalized patients. Atherosclerosis, 2017, 263, e189.	0.8	0
59	LDLR, PCSK9, and LDLRAP1 mutations in the same patient in a familial hypercholesterolemia (FH) family. Atherosclerosis, 2017, 263, e232.	0.8	O
60	Efficacy and safety of two dosages of canrenone as addâ€on therapy in hypertensive patients taking aceâ€inhibitors or angiotensin <scp> < scp> receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The <scp>ESCAPE< scp>â€<scp> T< scp> trial. Cardiovascular Therapeutics, 2017, 35, 47-54.</scp></scp></scp>	2.5	7
61	Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. Drug Design, Development and Therapy, 2017, Volume 11, 2293-2300.	4.3	4
62	Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R104-R114.	1.8	36
63	ED 05-4 NATRIURETIC PEPTIDES, METABOLIC SYNDROME AND HYPERTENSION. Journal of Hypertension, 2016, 34, e187.	0.5	O
64	OS 31-03 CLINICAL EFFECTIVENESS OF ANTI-HYPERTENSIVE THERAPY WITH ACEI OR ARB ASSESSED BY PLASMA RENIN ACTIVITY/PLASMA ALDOSTERONE CONCENTRATION RATIO. Journal of Hypertension, 2016, 34, e388.	0.5	0
65	Plasma Aldosterone, ANP, Hypertension and Stage A and B Heart Failure in the General Community. Journal of Cardiac Failure, 2016, 22, S75.	1.7	O
66	OS 10-01 PREVALENCE OF CAROTID PLAQUE AND ROLE OF CARDIOVASCULAR RISK FACTORS IN A VERY ELDERLY POPULATION. Journal of Hypertension, 2016, 34, e72.	0.5	3
67	PS 16-01 INSULIN AND GLUCOSE INDUCE NATRIURETIC PEPTIDE CLEARANCE RECEPTOR IN HUMAN ADIPOCYTES. Journal of Hypertension, 2016, 34, e466.	0.5	O
68	NT-proBNP and Its Correlation with In-Hospital Mortality in the Very Elderly without an Admission Diagnosis of Heart Failure. PLoS ONE, 2016, 11, e0153759.	2.5	29
69	Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4â€Year Followâ€Up. Journal of the American Heart Association, 2015, 4, .	3.7	22
70	Associations Between Body Mass Index, Ambulatory Blood Pressure Findings, and Changes in Cardiac Structure: Relevance of Pulse and Nighttime Pressures. Journal of Clinical Hypertension, 2015, 17, 147-153.	2.0	18
71	Circulating Aldosterone and Natriuretic Peptides in the General Community. Hypertension, 2015, 65, 45-53.	2.7	74
72	Chronic Kidney Disease Is Characterized by "Double Trouble―Higher Pulse Pressure plus Night-Time Systolic Blood Pressure and More Severe Cardiac Damage. PLoS ONE, 2014, 9, e86155.	2.5	27

#	Article	IF	CITATIONS
73	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 29-36.	2.2	7
74	Aldosterone: Marker and Predictor of Cardiorenal and Metabolic Disease in the General Community. Journal of Cardiac Failure, 2014, 20, S45-S46.	1.7	0
75	Hypertensive Heart Disease and Obesity: A Complex Interaction Between Hemodynamic and Not Hemodynamic Factors. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 81-87.	2.2	22
76	Nebivolol induces, via $\hat{1}^2$ 3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes. Journal of Hypertension, 2014, 32, 389-396.	0.5	28
77	Abstract 11026: Aldosterone Level in the General Community Predicts New Onset Cardiometabolic Disease. Circulation, 2014, 130, .	1.6	0
78	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 45-52.	2.2	57
79	Aldosterone in the General Community: Biomarker or Mediator of Cardiorenal and Metabolic Disease. Journal of Cardiac Failure, 2013, 19, S4.	1.7	0
80	Plasma Aldosterone Is Increased in Class 2 and 3 Obese Essential Hypertensive Patients Despite Drug Treatment. American Journal of Hypertension, 2012, 25, 818-826.	2.0	35
81	Summer does not always mean lower. Journal of Hypertension, 2012, 30, 1392-1398.	0.5	48
82	Obesity and Hypertension in Cardiac Hypertrophy. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 3-4.	2.2	3
83	Renal Artery Denervation for Treating Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 237-244.	2.2	19
84	Human Dedifferentiated Adipocytes Show Similar Properties to Bone Marrowâ€Derived Mesenchymal Stem Cells. Stem Cells, 2012, 30, 965-974.	3.2	119
85	Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. Journal of Clinical Investigation, 2012, 122, 1022-1036.	8.2	730
86	Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. Journal of Clinical Investigation, 2012, 122, 1584-1584.	8.2	5
87	Microalbuminuria and Left Ventricular Mass in Overweight and Obese Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 195-201.	2.2	9
88	Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 150-156.	2.6	60
89	A Unique MicroRNA Signature Associated With Plaque Instability in Humans. Stroke, 2011, 42, 2556-2563.	2.0	160
90	The Association of Left Ventricular Hypertrophy with Metabolic Syndrome is Dependent on Body Mass Index in Hypertensive Overweight or Obese Patients. PLoS ONE, 2011, 6, e16630.	2.5	44

#	Article	IF	Citations
91	Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism: Clinical and Experimental, 2010, 59, 734-741.	3.4	42
92	Angiotensinogen promoter variants influence gene expression in human kidney and visceral adipose tissue. Journal of Human Hypertension, 2010, 24, 213-219.	2.2	15
93	Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism: Clinical and Experimental, 2009, 58, 361-367.	3.4	42
94	In Vivo Physiological Transdifferentiation of Adult Adipose Cells. Stem Cells, 2009, 27, 2761-2768.	3.2	73
95	Endocannabinoids, Blood Pressure and the Human Heart. Journal of Neuroendocrinology, 2008, 20, 58-62.	2.6	20
96	Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. International Journal of Obesity, 2008, 32, 259-267.	3.4	56
97	A Human Fatty Acid Amide Hydrolase (FAAH) Functional Gene Variant Is Associated With Lower Blood Pressure in Young Males. American Journal of Hypertension, 2008, 21, 960-963.	2.0	18
98	The Clinical Significance of Metabolic Syndrome in Hypertension: Metabolic Syndrome Increases Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 59-62.	2.2	1
99	Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. Journal of Hypertension, 2008, 26, 831-843.	0.5	236
100	Angiotensin receptor blockers: dose does matter. Journal of Hypertension, 2008, 26, 607-608.	0.5	0
101	The 212A Variant of the APJ Receptor Gene for the Endogenous Inotrope Apelin is Associated With Slower Heart Failure Progression in Idiopathic Dilated Cardiomyopathy. Journal of Cardiac Failure, 2007, 13, 521-529.	1.7	27
102	The 460Trp allele of α-adducin increases carotid intima–media thickness in young adult males. Journal of Hypertension, 2006, 24, 697-703.	0.5	10
103	The functional HERG variant 897T is associated with Conn's adenoma. Journal of Hypertension, 2006, 24, 479-487.	0.5	14
104	Angiotensin receptor blockers and myocardial infarction: the importance of dosage. Journal of Hypertension, 2006, 24, 1679-1681.	0.5	1
105	Natriuretic Peptide Clearance Receptor Alleles and Susceptibility to Abdominal Adiposity. Obesity, 2004, 12, 351-356.	4.0	53
106	Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 65-73.	2.2	4
107	Genetic polymorphism of the renin???angiotensin???aldosterone system and arterial hypertension in the Italian population. Journal of Hypertension, 2003, 21, 1853-1860.	0.5	47
108	Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. Journal of Hypertension, 2003, 21, 1491-1496.	0.5	53

#	Article	IF	CITATIONS
109	Cardiovascular phenotype of young adults and angiotensinogen alleles. Journal of Hypertension, 2001, 19, 2171-2178.	0.5	15
110	Low Calorie Diet Enhances Renal, Hemodynamic, and Humoral Effects of Exogenous Atrial Natriuretic Peptide in Obese Hypertensives. Hypertension, 1999, 33, 658-662.	2.7	66
111	Natriuretic peptides receptors in human aldosterone-secreting adenomas. Journal of Endocrinological Investigation, 1999, 22, 514-518.	3.3	9
112	A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. Journal of Hypertension, 1999, 17, 1301-1305.	0.5	80
113	Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. Journal of Hypertension, 1997, 15, 1695-1698.	0.5	173
114	Cardiovascular Phenotype of a Mouse Strain With Disruption of Bradykinin B 2 -Receptor Gene. Circulation, 1997, 96, 3570-3578.	1.6	114
115	Angiotensin converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population. Journal of Hypertension, 1995, 13, 1593???1596.	0.5	14
116	Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. Journal of Hypertension, 1995, 13, 1241-1246.	0.5	91
117	Urinary kallikrein excretion and blood pressure response to angiotensin converting enzyme inhibitors and calcium antagonists in hypertensive patients. Journal of Hypertension, 1993, 11, 725-730.	0.5	6
118	Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues. Journal of Hypertension, 1993, 11, S214???S215.	0.5	33
119	A novel endothelial tyrosine kinase cDNA homologous to platelet-derived growth factor receptor cDNA. Biochemical and Biophysical Research Communications, 1992, 186, 706-714.	2.1	21
120	Renin-Angiotensin-System Inhibitors Are Associated With Lower In-hospital Mortality in COVID-19 Patients Aged 80 and Older. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3